Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients

K Cowman, A Miller, Y Guo, MH Chang… - Journal of …, 2023 - academic.oup.com
Objectives To assess and compare subsequent hospital admissions within 30 days for
patients after receiving a prescription for either oral nirmatrelvir/ritonavir or oral molnupiravir …
被引用次数：3 相关文章
[PDF] researchgate.net

[PDF][PDF] Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients

K Cowman, A Miller, Y Guo, MH Chang… - J Antimicrob …, 2023 - researchgate.net
Objectives: To assess and compare subsequent hospital admissions within 30 days for
patients after receiving a prescription for either oral nirmatrelvir/ritonavir or oral molnupiravir …

Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients

K Cowman, A Miller, Y Guo… - Journal of …, 2023 - einstein.elsevierpure.com
Objectives: To assess and compare subsequent hospital admissions within 30 days for
patients after receiving a prescription for either oral nirmatrelvir/ritonavir or oral molnupiravir …

Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients.

K Cowman, A Miller, Y Guo, MH Chang, T McSweeney… - 2023 - cabidigitallibrary.org
Objectives: To assess and compare subsequent hospital admissions within 30 days for
patients after receiving a prescription for either oral nirmatrelvir/ritonavir or oral molnupiravir …

Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients

K Cowman, A Miller, Y Guo… - The Journal of …, 2023 - pubmed.ncbi.nlm.nih.gov
Objectives To assess and compare subsequent hospital admissions within 30 days for
patients after receiving a prescription for either oral nirmatrelvir/ritonavir or oral molnupiravir …

Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients.

K Cowman, A Miller, Y Guo, MH Chang… - The Journal of …, 2023 - europepmc.org
To assess and compare subsequent hospital admissions within 30 days for patients after
receiving a prescription for either oral nirmatrelvir/ritonavir or oral molnupiravir. We …
[PDF] archive.org

[PDF][PDF] Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients

K Cowman, A Miller, Y Guo, MH Chang… - J Antimicrob …, 2023 - scholar.archive.org
Objectives: To assess and compare subsequent hospital admissions within 30 days for
patients after receiving a prescription for either oral nirmatrelvir/ritonavir or oral molnupiravir …

Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients

K Cowman, A Miller, Y Guo, MH Chang… - Journal of …, 2023 - academic.oup.com
Objectives To assess and compare subsequent hospital admissions within 30 days for
patients after receiving a prescription for either oral nirmatrelvir/ritonavir or oral molnupiravir …